natgillin/translations-raw huggingface dataset:
Expanded articles containing the self-extinguishing expandable composition according to any of claims 2, 8, 9, 10, 11, 13-15, having a density ranging from 5 to 50 g/l and a thermal insulation capacity, expressed by a thermal conductivity ranging from 25 mW/mK to 50 mW/mK, measured according to the standard DIN 52612. 
Ekspandirani artikli, naznačeni time što sadrže samougasivu ekspandabilnu mješavinu u skladu s bilo kojim od patentnih zahtjeva 2, 8, 9, 10, 11, 13-15, s gustoćom u rasponu od 5 do 50 g/1 i sposobnošću za toplinsku izolaciju, izraženu toplinskom vodljivošću u rasponu od 25 mW/mK do 50 mW/mK, izmjereno u prema standardu DIN
In a more particular embodiment, the conjugated nucleic acid molecule has one of the following formulae: 
2. < Konjugirana molekula nukleinske kiseline, naznačena time što ima jednu od sljedećih formula: ČI
When the attachment portion is structured in layers as explained above, the polyethylene on the surfaces of the attachment portion forms adhesive layers, which bond the attachment portion in position during the lamination taking place at a higher temperature. 
Kada se predio za povezivanje izvede u slojevima, kao što je to gore objašnjeno, polietilen na površinama predjela za povezivanje stvara ljepljive slojeve, koji povezuju predio za povezivanje u odabranom položaju za vrijeme spajanja slojeva, što se događa kod povišene temperature.
A rat trap according to claim 1, characterised in that the first sensor is adapted for sensing infrared light. 
Zamka za štakore prema zahtjevu 1 naznačena time da su sredstva za kontrolu sadržana u kućištu za bateriju.
The invention also proposes a system comprising a civil engineering structure and a damper arranged in order to damp the vibrations of at least one pair of stay cables of the civil engineering structure according to the above-mentioned method, said damper being connected to the stay cables of said pair and having a first stiffness in response to tensile stress and a second stiffness in response to compressive stress, the first stiffness being greater than the second stiffness. 
Postupak ublažavanja vibracija barem jednog para susjednih kablova (4a, 4b) građevinske strukture (1), pri čemu su kablovi navedenog para povezani amortizerom (6), naznačen time što navedeni amortizer (6) ima prvu čvrstoću kao odgovor na vlačnu napetost i drugu čvrstoću kao odgovor na tlačnu napetost, prva čvrstoća je veća od druge čvrstoće.
X is selected from the group consisting of halogen, -CN, -CO2R15, -C(=O)NR15R16, -NR15R16, -OR15, -SO2R7, and -P(=O)R8R9; and R15 and R16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH2, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be optionally substituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted; 
Ris je izabran iz grupe koju čine (Â«C=O)ORis, -OR:s, alkil 1 aril, pri čemu svaki alkil 1 aril mogu biti supstituirani; 1 Ris je izabran iz grupe koju čine H, acil, alkenil, alkoksil, OH, NH,, alkil, alkilamino, aril, alkilaril, cikloalkil, cikloalkilalkil, heteroaril, heterociklil 1 heterociklilalkil, gde svaki acil, alkenil, alkoksil, alkil, alkilamino, aril, alkilaril, cikloalkil, cikloalkilalkil, heteroaril, heterociklil 1 heterociklilalkil može biti supstituiran; i njegovi enantiomeri, diastereomeri, tautomeri, farmaceutski prihvatljive soli, hidrati, solvati i kompleksi. Spoj prema patentnom zahtjevu 1 predstavljen strukturom: šo
Apart from applications through dry powder inhalers the compositions of the invention can be administered in aerosols which operate via propellant gases or by means of so-called atomisers, via which solutions of pharmacologically-active substances can be sprayed under high pressure so that a mist of inhalable particles results. 
Osim primjene putem inhalatora za suhi prašak pripravci sukladno predmetnom izumu mogu se primjenjivati putem aerosola s potisnim plinovima ili putem tzv. atomizatora, u kojima se otopine farmakoloških djelatnih tvari mogu raspršiti pod visokim tlakom tako da se dobije maglica čestica za udisanje.
Subsequently, the dried raw veneer is cut to size and is sorted according to qualities. 
Nakon toga se osušeni sirovi furnir reže na potrebnu veličinu i razvrstava se prema kvaliteti.
Special details: All hydrogen atoms were placed in idealised positions and refined using a riding model, except those of the NH and OH which were located in the difference map and refined using restraints. 
Posebni detalji: Svi vodikovi atomi su smješteni u idealizirane položaje i namješteni su uporabom modela jahanja, osim onih NH i OH koji su smješteni u različite mape 1 koji su usklađeni uporabom ograničenja.
The composition of claims 1-9 wherein the hydrophobic medium comprises castor oil or glyceryl tricaprylate or glyceryl tributyrate or a combination thereof. 
Pripravak prema zahtjevima 1-9 naznačen time da hidrofobni medij sadrži ricinusovo ulje ili gliceril trikaprilat ili gliceril tributirat ili njihovu kombinaciju.
The method according to claim 1, wherein: the sending, by the terminal, the encoded information to the data sending end specifically comprises: sending, by the terminal, the encoded information through a physical uplink control channel PUCCH or a physical uplink shared channel PUSCH. 
Postupak prema zahtjevu 1, naznačen time da: slanje, pomoću terminala, kodirane informacije prema strani koja šalje podatke specifično sadrži: slanje, pomoću terminala, kodirane informacije kroz kontrolni kanal fizičke uzlazne veze, PUCCH ili dijeljeni kanal fizičke uzlazne veze, PUSCH.
Salts suitable for compounds of the formula I—depending on the substitution—are all acid addition salts but, in particular, all salts with bases. 
Soli prikladne za spojeve formule I - ovisno o supstituciji - su sve kiselinske adicijske soli, ali i posebno, sve soli s bazama.
BACKGROUND OF THE INVENTION Presently there are in use ski boots constituted by a shell to which there is downwardly connected a sole, having a tip and a heel connectable to predisposed bindings fixed to a ski; the shell, usually provided in rigid or semi-rigid plastic material, covers approximately entirely the foot of the user. 
Cipele za skijanje, koje se sada upotrebljavaju, imaju plašt na koji je dalje prema dolje spojen potplat, koji ima okov 1 petu, koji se mogu spojiti s prethodno postavljenim vezovima na skiju, a plašt, izrađen obično od krutog ili polukrutog plastičnog materijala, pokriva približno cijelo stopalo korisnika.
Use according to claim 31, wherein the surface-reacted natural calcium carbonate is used in combination with the polymeric flocculant as defined in one of the claims 18 to 24. A composite material comprising the surface-reacted natural calcium carbonate as defined in one of the claims 1 to 17 and at least one of the impurities as defined in one of the claims 27 to 29. 
Kompozitni materijal dobiven postupkom prema bilo kojem od zahtjeva 1 do 19, koji sadrži površinski-reagirani prirodni kalcij karbonat kao što je definiran u jednom od zahtjeva 1 do 15 i barem jednu od nečistoća izabranih iz nečistoća teških metala, organskih nečistoća, mikroorganizama, policikličnih spojeva, kolesterola i spojeva koji izazivaju endokrine poremećaje, te poželjno nadalje sadrži aktivni ugljen.
Specific turbidity remains substantially constant during D5W dilution, until the IL-2 concentration drops below about 0.1mg/ml. 
Specifično zamućenje ostaje u biti konstantnim za vrijeme razrjeđivanja u DSW, sve dok IL-2 koncentracija ne padne ispod oko 0,1 mg/ml.
wherein each variant comprises up to five conservatively modified amino acid substitutions; 
gdje svaka varijanta sadrži do jednu konzervativno modificiranu aminokiselinsku supstituciju;
FIG. 1 schematically shows an example of a plant according to the invention for manufacturing steel strips being wound in coils, having minimum thickness until 1 mm or sheets of thickness up to a maximum of 100 mm; 
shematski prikazuje primjer postrojenja prema ostvarenju izuma za proizvodnju čeličnih traka koje su namotane, imaju debljinu najmanje do 1 mm ili limova debljine do najviše 100 mm;
At the upper surface or, preferably, at the lower surface of such second seat 21, there is provided a toothing 22 which is transverse to the same second appendix 20. 
Na gornjoj površini ili, ponajprije, na donjoj površini tog drugog dosjeda 21, načinjeno je nazubljenje 22, koje je poprečno u odnosu na isti drugi nastavak 20.
In a preferred embodiment, a sustained release composition containing from 10 to 15 milligrams of 4-aminopyridine is administered twice daily. 
Sastav prema zahtjevu 1, naznačen time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 5 do 10 miligrama aminopiridina.
from a few ppm, advantageously from 10 ppm, to 2%, preferably from 10 ppm to 1% by weight, relative to the total weight of the composition, of at least one odor-masking agent b) as defined previously, preferably the masking agent Ci; and 
Pripravak prema zahtjevu 22, koji sadrži: a) 80% težine DMSO; b) od 10 ppm do 2%, poželjno od 10 ppm do 1% težine, u odnosu na ukupnu težinu pripravka, sredstva za maskiranje mirisa koje obuhvaća:
The vaccine of claim 2, wherein the at least one inactivated Salmonella of the Salmonella B group is Salmonella Typhimurium. 
Cjepivo prema zahljevu 2, naznačeno time, da najmanje jedna neaktivirana Salmonella od Salmonella skupine B je Salmonella Typhimurium.
in general, the course of reactions was followed by TLC and/or analytical LCMS, and reaction times are given for illustration only; 
(iv) općenito je tijek reakcije praćen sa TLC i/ili analitičkom LCMS, a reakcijska vremena su dana samo radi ilustracije;
95% to 100% by weight of a polyethylene glycol having an average molecular weight of from 4000 to 8000; and 
95% do 100 masenih % polietilen glikola koji ima prosječnu molekularnu težinu od 4000 do 8000; i ii.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fluopyram. 
spoja formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i spoj fenpropidin.
According to the present invention, still more preferable antibody include (a) a heavy chain variable region (HCVR) represented by the amino acid sequence of SEQ ID NO:10 and (b) a light chain variable region (LCVR) represented by the amino acid sequence of SEQ ID NO:12. 
Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1 ili 2, naznačen/o time, da obuhvaća: a) jaki lanac (H-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:2 ili 6; 1 b) slabi lanac (L-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:4 ili 8.
The complex according to claims 3 or 4, where Q is -(CH2)n-, n is an integer from 4 to 8, preferably 6, Y is -CH2-COOH and the radioisotope is Y-90. 
Kompleks prema patentnim zahtjevima 3 ili 4, naznačen time što je Q jednako Â«(CH>),-, n je cijeli broj od 4 do 8, poželjno 6, Y je -CH,-COOH i radioaktivni izotop je Y-90.
The nozzle shaft according to claim 1, wherein the nozzle shaft is manufactured of steel. 
Mlaznica propelera prema patentnom zahtjevu 1 ili 2, naznačena time da osovina (20) mlaznice je proizvedena od čelika.
A method of forming a buoyancy system (2), characterized in that the method includes the steps of: providing a plurality of floating elements (1) in accordance with claim 1; providing at least one elongated connecting element (22) selected from a group comprising a chain, a rope, a wire and a rubber band; 
Postupak oblikovanja sustava uzgona (2), naznačen time što postupak uključuje korake: a) = osiguravanje mnoštva plutajućih elemenata (1) prema patentnom zahtjevu 1; b) osiguravanje barem jednog izduženog spojnog elementa (22) odabranog iz skupine koja sadrži lanac, uže, žicu i gumenu traku;
Method for treating water at low cost, according to claim 7, wherein the information received by the coordination means is obtained by empirical methods. 
Postupak za obradu vode uz nizak trošak, prema zahtjevu 1, naznačen time što se informacije koje primaju koordinacijska sredstva dobivaju vizualnim pregledom, algoritmima koji se temelje na iskustvu, elektronskim detektorima ili njihovim kombinacijama.
of circular cross section in the region of interaction with the mount structure; and/or 
je kružnog presjeka u području interakcije s konstrukcijom nosača (11); i / ili
Cation Exchange material (Sigma-Aldrich, Dowex® 50WX4-400 strong cation exchange) was brought into the H+ form with a 1M aqueous HCl solution and thoroughly washed with distilled water until the washings were neutral. 
Kation izmjenjivački materijal (Sigma-Aldrich, Dowex* 50WX4-400 jaki kationski izmjenjivač) je doveden u H* oblik pomoću IM vodene otopine HCI i temeljito ispran s destiliranom vodom, dok tekućina od ispiranja nije bila neutralna.
PTA-5543; a monoclonal antibody that binds to an epitope comprising residues 82-87 of the human CD40 sequence shown in SEQ ID NO:10 or SEQ ID NO:12; 
PTA-5543; b) monoklonalnog antitijela koje se veže za epitop koji sadrži ostatke 82-87 humane CD40 sekvence prikazane u SEQ ID br.:10 ili SEQ ID br.:12;
n is an integer of 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof. 
X predstavlja kisik ili sumpor; nje 1, i/ili njegovi geometrijski izomeri i/ili stereoizomeri i/ili dijastereomeri i/ili njegove soli iili njegovi hidrati i/ili solvati.
Alternatively, the hardenable resin can be a material with active functional groups that can condense upon chemically reaction. 
Alternativno smola koja očvršćuje može biti materijal iz klase smola koje uključuju funkcionalne skupine koji se mogu kondenzirati nakon kemijske reakcije.
Use of a 9- cis- retinal derivative having a structure represented by Formula I wherein A is CH2OR and R forms a retinyl ester, in the preparation of a medicament for use in the treatment of an endogenous 11- cis -retinal deficiency in a human subject. 
Upotreba derivata 9-cis-retinala čija je struktura predstavljena Formulom I, [image] pri čemu A predstavlja CH2OR, a R tvori retinil ester, naznačena time, da je to upotreba za pripravu lijeka za liječenje endogene deficijencije 11-cis- retinala kod ljudskog subjekta.
2-10%, and at least one acrylic component 
2-10%,1 najmanje jednu akrilnu komponentu
is prepared by reaction of an ester of the formula (IVa) in which T1 is (C1-C4)-alkyl with formamide. The present invention further provides a process as described above, characterized in that an ester of the formula (IVa) is prepared by cyclization of the 5-aminopyrazole derivative (IIa) 
T' je (C,-C,)-alkil s formamidom i spoj s formulom (V) se dehidrira da se dobije spoj s formulom (VI). 2. | Postupak prema zahtjevu 1, naznačen time što se ester s formulom (IVa) priprema pomoću ciklizacije derivata 5-aminopirazola s formulom 15
Y is a linear alkylene group comprising 1 to 4 carbon atoms, provided that when X is a single bond, the moiety (CH2)n—X—Y is a trimethylene or pentamethylene group; and 
Y predstavlja ravnu alkilensku skupinu koja ima 1 do 4 ugljikovih atoma, pod uvjetom da kada X predstavlja jednostruku vezu polovica (CH),-X-Y predstavlja trimetilensku ili pentametilensku skupinu; a
1; FIG. 3 shows part of a second sampler according to the invention in a first position; 
Slika 3 prikazuje dio druge naprave za uzimanje uzorka, koja je u skladu s ovim, izumom u prvom položaju;
10% to 20% by weight of a compound of formula (1) as the sodium salt form; 
do 20 masenih % spoja formule (1) u obliku natrijeve soli;
The method of E 4, wherein the first treatment period ends within 30 days after disappearance of all symptoms of the AOID. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 4, naznačen time, da prvo razdoblje liječenja završava unutar 30 dana nakon nestanka svih simptoma AOID.
The communication apparatus according to claim 1, wherein the first frame configuration pattern and the second frame configuration pattern share at least one common transmission timing of an uplink subframe. A communication method comprising: 
Uređaj bazna stanica prema zahtjevu 1, naznačen time da prvi obrazac konfiguracije okvira za Primarnu Stanicu i drugi obrazac konfiguracije okvira za Sekundarnu Stanicu dijele barem jedno zajedničko vrijeme prijenosa podokvira uzlazne veze.
and R6 are independently selected from hydrogen, halogen, COOH; CN; NH2; NO2; OH; C1-6 alkyl; substituted C1-6 alkyl; substituted or unsubstituted aryl or heteroaryl; R7; COOR7; CONHR7; CON(R7)2; OR7; NHR7; N(R7)2; R7-alkoxy; R7-haloalky; and R7-haloalkoxy; or R5 and R6, taken together with their bonded carbons, form a substituted or unsubstituted unsaturated 5- or 6- membered carbocyclic ring or a substituted or unsubstituted saturated 5-, 6-, or 7-membered carbocyclic ring, wherein 
i R6 su neovisno odabrani od vodika, halogena, COOH; CN; NH2; NO2; OH; C1-6 alkila; supstituiranog C1-6 alkila; supstituiranog ili nesupstituiranog arila ili heteroarila; R7; COOR7; CONHR7; CON(R7)2; OR7;NHR7; N(R7)2; R7-alkoksija; R7-haloalkila; i R7-haloalkoksija; ili R5 i R6, zajedno s njihovim vezanim ugljicima, formiraju supstituirani ili nesupstituirani 5-ero ili 6-eročlani karbociklički prsten ili supstituirani ili nesupstituirani zasićeni 5-ero, 6-ero, ili 7-eročlani karbociklički prsten, gdje karbociklički prsten može biti heterokarbociklički prsten koji sadrži najmanje jedan hetero atom odabran iz O, N i S, gdje supstituirani prsten sadrži najmanje jedan vodik, halogen, COOH; CN; NH2; NO2; OH; C1-6 alkil; supstituirani C1-6 alkil; supstituirani ili nesupstituirani aril ili heteroaril; R7; COOR7; CONHR7; CON(R7)2; OR7; NHR7; N(R7)2; R7-alkoksi; R7-haloalkil; ili R7-haloalkoksi;
The process of claim 1, wherein R1 is H. 
Postupak dobivanja spoja Formule (I):
The method of any of claims 1 to 11, wherein the 1st reactant is a compound of formula R2-C≡C-H II, wherein R2 is a substituent selected from the group consisting of C1-6-alkyl, C3-10-cycloalkyl, aryl, heteroaryl and aralkyl, and wherein each cycloalkyl, aryl, heteroaryl or aralkyl can carry one or more further substituents selected from the group consisting of C1-6-alkyl, C1-6-alkoxy and tri-C1-6-alkylsilyloxy. 
Postupak prema bilo kojem zahtjevu od 1 do 11, naznačen time, da je prvi reaktant spoj formule R'-C=C-H II, gdje R? je supstituent odabaran iz skupine koja se sastoji od C,_s-alkila, C3,9-Cikloalkila, arila, heteroarila i aralkila, pri čemu svaki cikloalkil, aril, heteroaril ili aralkil može nositi jednog ili više daljnjih supstituenata odabranih iz skupine koja se sastoji od C, s-alkila, C,.g-alkoksi 1 tri-C, g-alkilsililoksi.
A method for the treatment of a disease selected from the group consisting of Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and myasthenia gravis comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 18, ili njegove farmaceutski prihvatljive soli, za pripremanje lijeka za liječenje bolesti odabrane od Amiotrofne Lateralne Skleroze (ALS), Spinalne Mišićne Atrofije (SMA) i mijastenije gravis.
The umbrella as recited in claim 1, wherein an imaginary center axis of a first umbrella strut element and an imaginary center axis of a second umbrella strut element adjoining the first umbrella strut element adjacent to the first umbrella strut element, are askew to each other, and a span of shortest length between the imaginary center axis of the first umbrella strut element along the length of the first umbrella strut element and the imaginary center axis of the second umbrella strut element along the length of the second umbrella strut element does not intersect with an imaginary center axis of the central holding element. 
Kišobran kao što je navedeno u patentnom zahtjevu 1, naznačen time da se zamišljena središnja os potpornog elementa kišobrana i zamišljena središnja os potpornog elementa kišobrana koja joj je susjedna na prvoj strani međusobno mimoilaze i raspon izuzetno kratke duljine između zamišljene središnje osi potpornog elementa kišobrana i zamišljene središnje osi potpornog elementa kišobrana koja joj je susjedna na prvoj strani se ne presijeca sa zamišljenom središnjom osi središnjeg elementa držača.
X represents oxygen or sulphur; n is 1, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof. 
X predstavlja kisik ili sumpor; nje 1, i/ili njegovi geometrijski izomeri i/ili stereoizomeri i/ili dijastereomeri i/ili njegove soli iili njegovi hidrati i/ili solvati.
the pharmaceutical composition is in a form suitable for oral administration to a mammal, for example wherein the pharmaceutical composition is in an oral solid dosage form, and/or 
Farmaceutski pripravak prema zahtjevu 7, naznačen time da je navedeni farmaceutski pripravak u obliku pogodnom za oralno davanje sisavcu.
No. 5,130,061 relates to a process to obtain EPA and DHA as ethyl esters from crude fish oils, through transesterification with ethanol and acid catalyst (H2SO4), chromatography on silica gel and molecular distillation. 
US 5130061 se odnosi na postupak za dobivanje EPA i DHA kao etil estera iz sirovog ribljeg ulja, transesterifikacijom s etanolom 1 kiselinskim katalizatorom (H2SOy), kromatografijom na silikagelu 1 molekularnom destilacijom.
contacting the pre-incubated sample with HPVLPs, consisting predominantly of the VP1 protein of the JCV, immobilized on a solid substrate under conditions suitable for binding of a JCV antibody in the sample to an HPVLP; 
(b) stavljanju u kontakt predinkubiranog uzorka s HPVLP-ima, koji se pretežno sastoje od proteina VP1 iz JCV, imobiliziranih na čvrsti supstrat u uvjetima pogodnim za vezanje protutijela protiv JCV u uzorku na HPVLP;
The solid dosage form of claim 12, wherein the polymorphic crystalline form of a compound of Formula I is present in about 90% of the total weight of tiacumicins. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u najmanje99% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
The composition according to any one of the preceding claims, for use in the treatment of type II diabetes or obesity. 
Kompozicija prema patentnom zahtjevu 12, za uporabu u liječenju dijabetesa tipa II 1li pretilosti.
The process according to claim 1, wherein in step g) the liquid fraction of step f) is treated with an acid to reduce the pH of this liquid fraction by at least 1 pH unit. 
Proces prema zahtjevu 21 ili 22, naznačen time što se u koraku g) tekuća frakcija iz koraka f) obrađuje kiselinom radi snižavanja pH te tekuće frakcije za barem 1 pH jedinicu.
is selected from H, optionally substituted C1-C8 alkyl, and OR11, wherein said optional substituents arc one to three R10 groups; 
R/ je odabran od H, proizvoljno supstituiranog C,-C; alkila, te OR", pri čemu su navedeni nezavisni supstituenti jedna do tri R'" skupine; t>&
The obtained pellets are amorphous. 
Dobivene pelete su amorfne.
an excitation voltage (Vsend) signal from the sending end, where the PLL outputs a (Af) correction term for the frequency of the sending-end fundamental voltage. 
signalom pobudnog napona (Vsend) iz odašiljajućeg kraja, gdje iz PLL izlazi (Af) ispravljeni izraz za frekvenciju odašiljajućeg kraja temeljnog napona.
Suitable pharmaceutically acceptable carriers include water, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, and carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, and polyvinyl pyrrolidine. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačen time da je farmaceutski prihvatljiv nosač odabran iz skupa koji čine voda, otopine soli, alkoholi, ulja, želatina, ugljikohidrati, esteri masnih kiselina, hidroksimetilceluloza, i polivinil pirolidon.